Antibiotic News and Research

RSS

Antibiotics are drugs used to treat infections caused by bacteria and other microorganisms.

Researchers develop polymers that fluoresce in the presence of bacteria

Researchers at the University of Sheffield have developed polymers that fluoresce in the presence of bacteria, paving the way for the rapid detection and assessment of wound infection using ultra-violet light.

16 Sep 2011

New paper describes unique process that is central to induction of MSRA antibiotic resistance

A new paper by a team of University of Notre Dame researchers that included Shahriar Mobashery, Jeffrey Peng, Brian Baker and their researchers Oleg Borbulevych, Malika Kumararasiri, Brian Wilson, Leticia Llarrull, Mijoon Lee, Dusan Hesek and Qicun Shi describes a unique process that is central to induction of antibiotic resistance in the problematic bacterium methicillin-resistant Staphylococcus aureus.

16 Sep 2011

Longer looks: Fighting antibiotic resistance; a health care arms race video; the HVP debate

We won't stop the rising tide of infections until we develop a new business model to fight them. We are not quite on the brink of some dystopian Victorian future. But every year, the prognosis for infectious-disease patients gets a bit grimmer. … And more-powerful drugs tend to cost more than the old drugs. … Even in the rich world, death from infection still looms; MRSA alone kills thousands every year. And firms are not developing antibiotics as fast as they used to.

16 Sep 2011

Azithromycin gel may treat borreliosis in humans

Blood-sucking ticks are not just a nuisance, they can also transmit dangerous diseases. One of them is Lyme disease, which is caused by bacteria of the genus Borrelia, and requires a course of treatment with antibiotics lasting several weeks. LMU researchers have come up with a quicker alternative.

16 Sep 2011

Cempra's solithromycin demonstrates efficacy comparable to levofloxacin for CABP treatment

Cempra Pharmaceuticals today announced results from its Phase II clinical trial investigating the efficacy, safety and tolerability of oral administration of our fourth generation macrolide, solithromycin (CEM-101), a fluoroketolide antibiotic, in comparison with oral levofloxacin for the treatment of community-acquired bacterial pneumonia (CABP).

15 Sep 2011

China Botanic third-quarter net sales increase 33.6% to $12.4 million

China Botanic Pharmaceutical Inc., a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines in China, today announced financial results for the three months ended July 31, 2011.

15 Sep 2011

Without action to curb antibiotic resistance, some diseases may once again become untreatable

In this Atlantic Magazine opinion piece, Megan McArdle, senior editor at the Atlantic, echoes a warning by the FDA issued in 2001 which stated, "Unless antibiotic resistance problems are detected as they emerge, and actions are taken to contain them, the world could be faced with previously treatable diseases that have again become untreatable, as in the days before antibiotics were developed."

15 Sep 2011

ASM to honor LA BioMed investigator for A. baumannii infection study

Ashraf Ibrahim, Ph.D., principal investigator at LA BioMed who specializes in infectious diseases, was recently honored by the American Society for Microbiology (ASM) and the ICAAC Program Committee in the area of Therapy and Prevention of Microbial Disease.

14 Sep 2011

Viewpoints: Burgess, Clancy and others on hospital infections; state health exchanges causing controversy

Hospital CEOs can do more than just prevent an outbreak of influenza in their facility this flu season: They can and must take action against antibiotic resistance, an urgent public health problem that affects us all. What does the flu have to do with antibiotic resistance and what can a hospital CEO do about it? Plenty, as it turns out.

13 Sep 2011

Taiwan residents to receive two month free access to The Cochrane Library

Taiwan residents will receive free access to The Cochrane Library in August and September 2011, in collaboration with the Taiwan Evidence Based Medicine Association at their Annual Conferencein September, whereDr. Charles Young, VP and Publishing Director for Global Clinical Solutions, atThe Cochrane Library's publisher, Wiley-Blackwell, will be presenting a session.

12 Sep 2011

Chemical biology researchers to meet at Scientific Oktoberfest in München

The "Scientific Oktoberfest" will be this year's meeting point for some of the internationally most distinguished researchers in the field of Chemical Biology. The so-called "CIPSM Fest of Chemical Biology" will be held from the 15th to the 16th of September in the Department of Chemistry of the Ludwig-Maximilians-Universität (LMU) München.

9 Sep 2011

Duties, role of clinical laboratory microbiologists could change significantly in the future

With the increasing availability of sophisticated technologies to rapidly diagnose and treat infectious diseases, the duties and the role of clinical laboratory microbiologists, who traditionally perform these tests, could see significant changes in the next few years. That is one of the conclusions of a series of reports published in a special supplement to the September 2011 Journal of Clinical Microbiology.

9 Sep 2011

Study identifies genes never before linked to antibiotic resistance in enterococci

An analysis of the genome of a superbug has yielded crucial, novel information that could aid efforts to counteract the bacterium's resistance to an antibiotic of last resort.

9 Sep 2011

Mass. Eye and Ear receives NIAID grant to coordinate Harvard-wide Project on Antibiotic Resistance

The Massachusetts Eye and Ear Infirmary has received an $11 million grant from the National Institute of Allergy and Infectious Disease, the largest National Institutes of Health grant in this hospital's187-year history, to coordinate the Harvard-wide Project on Antibiotic Resistance.

8 Sep 2011

Adding azithromycin to usual daily treatment for COPD reduces acute exacerbations by 27%

Richard Casaburi, Ph.D., M.D., principal investigator at Los Angeles Biomedical Research Institute (LA BioMed), is co-author of a recent study that should help improve the condition for the millions of individuals who suffer from chronic obstructive pulmonary disease, better known as COPD.

8 Sep 2011

First-ever comprehensive study of species origins of nature-derived drugs

In a first-ever comprehensive study of the species origins of nature-derived drugs, it is shown that drug-producing species are concentrated and clustered in a limited number of families, refuting the conventional view that as every nature species produces biologically active molecules, one can find drugs from almost any major block of species groups if one looks for them hard enough.

8 Sep 2011

BARDA awards GlaxoSmithKline contract for development of dual-purpose broad spectrum antibiotic

The federal government today issued a contract for advanced research and development of a dual-purpose broad spectrum antibiotic with potential to treat illnesses caused by bioterrorism threats such as plague and tularemia, as well as more certain life-threatening infections, known as Gram-negative infections, associated with prolonged hospitalization.

7 Sep 2011

GSK receives HHS' BARDA contract to support development of Gram-negative antibiotic, GSK2251052

Anacor Pharmaceuticals announced today that its partner, GlaxoSmithKline (GSK), has been awarded a contract with the U.S. Department of Health and Human Services' (HHS) Biomedical Advanced Research and Development Authority (BARDA) to support the ongoing development of GSK2251052 (GSK '052, formerly AN3665), a novel boron-based Gram-negative systemic antibiotic discovered by Anacor.

7 Sep 2011

Superbug structure deciphered

NDM-1, the enzyme responsible for antibiotic-resistant "superbugs," has had its structure deciphered by British scientists. NDM-1 (New Delhi metallo-beta-lactamase 1) emerged in India three years ago. It has the ability to break up, or hydrolyze, even carbapenems, the strongest class of antibiotics, making them ineffective, and has been found in a wide variety of pathogens. Antibiotic resistance is on the rise. More than 25,000 people in the European Union die every year from bacterial infections.

6 Sep 2011

NanoLogix to move R&D operations from Cincinnati to its headquarters in Hubbard

NanoLogix, an innovator in the accelerated detection and identification of microorganisms, announced today it will move its research and development operations from Cincinnati to its headquarters in Hubbard, Ohio.

6 Sep 2011

Antibiotic News and Research

Further Reading

Researchers develop polymers that fluoresce in the presence of bacteria

New paper describes unique process that is central to induction of MSRA antibiotic resistance

Longer looks: Fighting antibiotic resistance; a health care arms race video; the HVP debate

Azithromycin gel may treat borreliosis in humans

Cempra's solithromycin demonstrates efficacy comparable to levofloxacin for CABP treatment

China Botanic third-quarter net sales increase 33.6% to $12.4 million

Without action to curb antibiotic resistance, some diseases may once again become untreatable

ASM to honor LA BioMed investigator for A. baumannii infection study

Viewpoints: Burgess, Clancy and others on hospital infections; state health exchanges causing controversy

Taiwan residents to receive two month free access to The Cochrane Library

Chemical biology researchers to meet at Scientific Oktoberfest in München

Duties, role of clinical laboratory microbiologists could change significantly in the future

Study identifies genes never before linked to antibiotic resistance in enterococci

Mass. Eye and Ear receives NIAID grant to coordinate Harvard-wide Project on Antibiotic Resistance

Adding azithromycin to usual daily treatment for COPD reduces acute exacerbations by 27%

First-ever comprehensive study of species origins of nature-derived drugs

BARDA awards GlaxoSmithKline contract for development of dual-purpose broad spectrum antibiotic

GSK receives HHS' BARDA contract to support development of Gram-negative antibiotic, GSK2251052

Superbug structure deciphered

NanoLogix to move R&D operations from Cincinnati to its headquarters in Hubbard

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News